Display options
Cite
Kong Q, Wang M, Liao Z, et al. P2X(7) nucleotide receptors mediate caspase-8/9/3-dependent apoptosis in rat primary cortical neurons. Purinergic Signal. 2005;1(4):337-47doi: 10.1007/s11302-005-7145-5.
Kong, Q., Wang, M., Liao, Z., Camden, J. M., Yu, S., Simonyi, A., Sun, G. Y., Gonzalez, F. A., Erb, L., Seye, C. I., & Weisman, G. A. (2005). P2X(7) nucleotide receptors mediate caspase-8/9/3-dependent apoptosis in rat primary cortical neurons. Purinergic signalling, 1(4), 337-47. https://doi.org/10.1007/s11302-005-7145-5
Kong, Qiongman, et al. "P2X(7) nucleotide receptors mediate caspase-8/9/3-dependent apoptosis in rat primary cortical neurons." Purinergic signalling vol. 1,4 (2005): 337-47. doi: https://doi.org/10.1007/s11302-005-7145-5
Kong Q, Wang M, Liao Z, Camden JM, Yu S, Simonyi A, Sun GY, Gonzalez FA, Erb L, Seye CI, Weisman GA. P2X(7) nucleotide receptors mediate caspase-8/9/3-dependent apoptosis in rat primary cortical neurons. Purinergic Signal. 2005 Dec;1(4):337-47. doi: 10.1007/s11302-005-7145-5. Epub 2005 Dec 03. PMID: 18404518; PMCID: PMC2096553.
Copy Download .nbib Format: NLM
Share it on

Purinergic Signal. 2005 Dec;1(4):337-47. doi: 10.1007/s11302-005-7145-5. Epub 2005 Dec 03.

P2X(7) nucleotide receptors mediate caspase-8/9/3-dependent apoptosis in rat primary cortical neurons.

Purinergic signalling

Qiongman Kong, Min Wang, Zhongji Liao, Jean M Camden, Sue Yu, Agnes Simonyi, Grace Y Sun, Fernando A Gonzalez, Laurie Erb, Cheikh I Seye, Gary A Weisman

Affiliations

  1. Interdisciplinary Neuroscience Program, University of Missouri-Columbia, Columbia, Missouri, USA.

PMID: 18404518 PMCID: PMC2096553 DOI: 10.1007/s11302-005-7145-5

Abstract

Apoptosis is a major cause of cell death in the nervous system. It plays a role in embryonic and early postnatal brain development and contributes to the pathology of neurodegenerative diseases. Here, we report that activation of the P2X(7) nucleotide receptor (P2X(7)R) in rat primary cortical neurons (rPCNs) causes biochemical (i.e., caspase activation) and morphological (i.e., nuclear condensation and DNA fragmentation) changes characteristic of apoptotic cell death. Caspase-3 activation and DNA fragmentation in rPCNs induced by the P2X(7)R agonist BzATP were inhibited by the P2X(7)R antagonist oxidized ATP (oATP) or by pre-treatment of cells with P2X(7)R antisense oligonucleotide indicating a direct involvement of the P2X(7)R in nucleotide-induced neuronal cell death. Moreover, Z-DEVD-FMK, a specific and irreversible cell permeable inhibitor of caspase-3, prevented BzATP-induced apoptosis in rPCNs. In addition, a specific caspase-8 inhibitor, Ac-IETD-CHO, significantly attenuated BzATP-induced caspase-9 and caspase-3 activation, suggesting that P2X(7)R-mediated apoptosis in rPCNs occurs primarily through an intrinsic caspase-8/9/3 activation pathway. BzATP also induced the activation of C-jun N-terminal kinase 1 (JNK1) and extracellular signal-regulated kinases (ERK1/2) in rPCNs, and pharmacological inhibition of either JNK1 or ERK1/2 significantly reduced caspase activation by BzATP. Taken together, these data indicate that extracellular nucleotides mediate neuronal apoptosis through activation of P2X(7)Rs and their downstream signaling pathways involving JNK1, ERK and caspases 8/9/3.

References

  1. Neuroreport. 2004 Oct 25;15(15):2387-91 - PubMed
  2. J Physiol. 1999 Mar 1;515 ( Pt 2):377-83 - PubMed
  3. Annu Rev Pharmacol Toxicol. 2000;40:563-80 - PubMed
  4. J Neurosci. 2004 Jul 14;24(28):6307-14 - PubMed
  5. J Biol Chem. 1990 May 5;265(13):7424-31 - PubMed
  6. J Biol Chem. 2004 Apr 23;279(17):16918-26 - PubMed
  7. Pharmacol Rev. 2001 Mar;53(1):107-18 - PubMed
  8. J Neurosci. 2001 Sep 15;21(18):7143-52 - PubMed
  9. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):310-23 - PubMed
  10. J Biol Chem. 1997 Feb 28;272(9):5482-6 - PubMed
  11. Science. 2001 Apr 27;292(5517):727-30 - PubMed
  12. Ann N Y Acad Sci. 1990;603:275-85; discussion 285-6 - PubMed
  13. J Neurochem. 2002 Jun;81(6):1196-211 - PubMed
  14. J Cereb Blood Flow Metab. 2004 Apr;24(4):392-8 - PubMed
  15. J Physiol. 1999 Sep 1;519 Pt 2:335-46 - PubMed
  16. Am J Physiol Cell Physiol. 2003 Feb;284(2):C571-81 - PubMed
  17. J Biol Chem. 2000 Sep 1;275(35):26792-8 - PubMed
  18. Trends Pharmacol Sci. 2003 Feb;24(2):52-5 - PubMed
  19. J Biol Chem. 1999 Jul 16;274(29):20049-52 - PubMed
  20. Br J Anaesth. 2000 Apr;84(4):476-88 - PubMed
  21. Nucleic Acids Res. 1978 Oct;5(10):3775-99 - PubMed
  22. Eur J Pharmacol. 1978 May 15;49(2):145-9 - PubMed
  23. J Endotoxin Res. 2003;9(4):256-63 - PubMed
  24. Cell. 1997 Nov 14;91(4):479-89 - PubMed
  25. Cell. 1998 Aug 21;94(4):481-90 - PubMed
  26. Brain Res. 2004 Jul 23;1015(1-2):169-74 - PubMed
  27. J Biol Chem. 2000 Mar 31;275(13):9303-7 - PubMed
  28. Exp Cell Res. 1999 Jul 10;250(1):203-12 - PubMed
  29. J Cell Biol. 1999 Jan 25;144(2):281-92 - PubMed
  30. J Biol Chem. 1999 Jul 30;274(31):21932-6 - PubMed
  31. Prog Biochem Pharmacol. 1980;16:141-54 - PubMed
  32. J Biol Chem. 1998 Jun 26;273(26):16589-94 - PubMed
  33. Mol Pharmacol. 2003 Mar;63(3):706-13 - PubMed
  34. Br J Pharmacol. 2002 Apr;135(7):1616-26 - PubMed
  35. Glia. 2002 Nov;40(2):156-63 - PubMed
  36. J Exp Med. 1997 Feb 3;185(3):579-82 - PubMed
  37. J Biol Chem. 1998 Oct 16;273(42):27170-5 - PubMed
  38. J Neurosci. 2001 Dec 15;21(24):9519-28 - PubMed
  39. Nat Med. 2004 Aug;10(8):821-7 - PubMed
  40. J Cell Physiol. 1984 May;119(2):211-9 - PubMed
  41. Eur J Pharmacol. 1999 Jul 2;376(1-2):127-38 - PubMed
  42. J Neurosci. 2003 Feb 15;23(4):1320-8 - PubMed
  43. J Neurochem. 2003 Dec;87(6):1413-26 - PubMed
  44. Cell. 1997 Nov 14;91(4):443-6 - PubMed
  45. Neuroscience. 2004;123(3):761-8 - PubMed
  46. J Biol Chem. 2002 Oct 25;277(43):40775-81 - PubMed
  47. Am J Physiol Cell Physiol. 2004 Nov;287(5):C1349-58 - PubMed
  48. J Neurosci. 2001 Sep 15;21(18):7135-42 - PubMed
  49. Neuroscience. 1999;91(3):1171-81 - PubMed
  50. Cancer Res. 2004 Nov 15;64(22):8148-51 - PubMed
  51. Neuropharmacology. 1997 Sep;36(9):1277-83 - PubMed
  52. J Biol Chem. 2003 Apr 11;278(15):13309-17 - PubMed
  53. Br J Pharmacol. 2003 Oct;140(3):507-19 - PubMed
  54. Eur J Pharmacol. 2004 Jan 1;483(1):5-17 - PubMed
  55. Neurochem Int. 2004 Dec;45(7):987-93 - PubMed
  56. FEBS Lett. 1998 Nov 13;439(1-2):26-30 - PubMed
  57. J Immunol. 2001 Aug 15;167(4):1871-6 - PubMed
  58. Blood. 2001 Feb 1;97(3):587-600 - PubMed
  59. Circulation. 2002 Nov 19;106(21):2720-6 - PubMed
  60. Invest Ophthalmol Vis Sci. 2004 Mar;45(3):1026-32 - PubMed
  61. Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):324-39 - PubMed
  62. Cell. 1998 Aug 21;94(4):491-501 - PubMed
  63. Science. 1996 May 3;272(5262):735-8 - PubMed

Publication Types

Grant support